Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).
Saved in:
| Title: | Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet). |
|---|---|
| Authors: | Bansal A; Department of Gastroenterology, University of Kansas Medical Center, and University of Kansas Cancer Center, Kansas City, KS, United States., Stoffel EM; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States., Lim R; Department of Gastroenterology, Dana-Farber Cancer Institute, Boston, MA, United States., Stanich PP; Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, United States., Patel SG; Department of Medicine-Gastroenterology, University of Colorado, Aurora, CO, United States., Burke CA; Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH, United States., Hall MJ; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, United States., Singh A; Division of Gastroenterology, University of California, San Francisco, San Francisco, CA, United States., Boardman LA; Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN, United States., Samadder NJ; Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Phoenix, AZ, United States., Ballestar V; Department of Medicine, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico., Muller C; Division of Gastroenterology and Hepatology, Northwestern University, Chicago, IL, United States., Scott AJ; Division of Hematology and Oncology, University of Arizona Cancer Center, Tucson, AZ, United States., Benante KA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Xu Y; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Eickhoff J; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States., Hyun M; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States., Zaborek J; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States., Aquila L; Frontier Science Foundation, Amherst, NY, United States., Umar A; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Szabo E; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Della'Zanna G; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Richmond E; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Bengtson L; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Schlom J; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Donahue RN; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Toney NJ; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Horn LA; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Palena C; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Gulley JL; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Samaddar S; Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, United States., Moore DF Jr; Cancer Center of Kansas, Wichita, KS, United States., Sharma P; Department of Hematology and Oncology, Virginia Commonwealth University Medical Center, Richmond, VA, United States., Madan R; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States., Hurley KE; Neurological Institute, Department of Psychiatry & Psychology, Center for Adult Behavioral Health, Cleveland Clinic, Cleveland, OH, United States., Soon-Shiong P; ImmunityBio, Culver City, CA, United States., Gabitzsch E; ImmunityBio, Culver City, CA, United States., Sender L; ImmunityBio, Culver City, CA, United States., Brenner D; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States., Schuetze S; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States., Djuric Z; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States., Barroilhet LM; Division of Gynecologic Oncology, University of Wisconsin, Madison, WI, United States., Thompson P; Department of Physiology, University of Arizona Cancer Center, Tucson, AZ, United States., Bauman J; Division of Hematology and Oncology, University of Arizona Cancer Center, Tucson, AZ, United States., Khan SA; Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Vilar E; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2026 May 19; Vol. 17, pp. 1809281. Date of Electronic Publication: 2026 May 19 (Print Publication: 2026). |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1809281 |
